NAFDAC Drug Evaluation & Research (DER) Directorate Guidelines for Clinical Investigation of Medicinal Products in Pediatric Population
Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria
The guideline has an overall objective to encourage and facilitate timely paediatric medicinal product development in Nigeria. It provides an outline of critical issues in paediatric drug development and the approaches to the safe, efficient and ethical study of medicinal products in the paediatric population.
Process Flow
Department of Drug Evaluation and Research ⬤
Office of the Director General NAFDAC ⬤
Office of the Permanent Secretary, Ministry of Health ⬤
Office of the Minister of State for Health ⬤
Office of the minister for health ⬤
Federal Executive Council ⬤
Contacts
Ijeoma U. Nwankwo
Director
National Agency for Food and Drug Administration and Control (NAFDAC)
Moji Adeyeye
Director General
National Agency for Food and Drug Administration and Control (NAFDAC)
Mahmuda Mamman
Permanent Secretary
Ministry of Health
Adeleke O. Mamora
Honourable Minister of State
Ministry of Health
Osagie Ehanire
Honourable Minister
Ministry of Health
Muhammadu Buhari
President of the Federal Republic of Nigeria
NAFDAC Drug Evaluation & Research (DER) Directorate Guidelines for Clinical Investigation of Medicinal Products in Pediatric Population Current Version
January 2022
The guideline has an overall objective to encourage and facilitate timely paediatric medicinal product development in Nigeria. It provides an outline of critical issues in paediatric drug development and the approaches to the safe, efficient and ethical study of medicinal products in the paediatric population.
Thank you for requesting an expert analysis
A member of our team will review your request and reply back to the email address on file.